NR2E3 mutation-associated retinal degeneration Market

DelveInsight’s “NR2E3 mutation-associated retinal degeneration – Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the NR2E3 mutation-associated retinal degeneration, historical and forecasted epidemiology as well as the NR2E3 mutation-associated retinal degeneration market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

The NR2E3 mutation-associated retinal degeneration market report provides current treatment practices, emerging drugs, NR2E3 mutation-associated retinal degeneration market share of individual therapies, and current and forecasted NR2E3 mutation-associated retinal degeneration market size from 2019 to 2032, segmented by seven major markets. The report also covers current NR2E3 mutation-associated retinal degeneration treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

 

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

 

Study period: 2019–2032

 

NR2E3 mutation-associated retinal degeneration Understanding and Treatment Algorithm

The DelveInsight’s NR2E3 mutation-associated retinal degeneration market report gives a thorough understanding of NR2E3 mutation-associated retinal degeneration by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. Retinal degenerations encompass a complex group of disorders that lead to the loss of photoreceptors, the light-sensing cells of the eye. Such disorders are the leading cause of untreatable sight loss in the industrialized world, and currently, there is a lack of effective treatments.

NR2E3 (PNR), a nuclear receptor specifically expressed in photoreceptors, represses cone-specific genes and activates several rod-specific genes. NR2E3 is a genetic modifier that rescues retinal degeneration and promotes homeostasis in multiple models of retinitis pigmentosa. Mutations in NR2E3 cause retinitis pigmentosa (RP), enhanced S-cone syndrome (ESCS), Goldmann-Favre syndrome (GFS), and clumped pigmentary retinal degeneration (CPRD). This gene produces a large isoform encoded in 8 exons and a previously unreported shorter isoform of 7 exons, whose function is unknown.

A common feature of these syndromes is a uniquely abnormal electroretinographic pattern in which there is a maximal response to short wavelengths and virtually no change in response waveform to light and dark adaptation; this is invariably associated with nyctalopia and some long- and middle-wavelength–sensitive cone dysfunction.

 

NR2E3 mutation-associated retinal degeneration diagnosis

Retinal disorders come in different forms and diagnosis of NR2E3 mutation-associated retinal degeneration is one challenging aspect as the mutation in the gene causes severe ailments. Molecular studies of this gene are required to make the diagnosis that is most relevant for understanding the pathogenesis of this spectrum of conditions and potentially provide some form of therapy for affected patients. Proper diagnosis is aided by Electroretinography (ERG) test, Optical coherence tomography scan, and Fundus autofluorescence test.

 

NR2E3 mutation-associated retinal degeneration treatment

Currently, no branded treatments are available to cure retinal degeneration, but some can help prevent the condition from worsening. The treatment for this condition varies according to the stage and type.

 

NR2E3 mutation-associated retinal degeneration Epidemiology

The NR2E3 mutation-associated retinal degeneration epidemiology section provides insights into the historical and current NR2E3 mutation-associated retinal degeneration patient pool and forecasted trends for seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the NR2E3 mutation-associated retinal degeneration report also provides the diagnosed patient pool, their trends, and assumptions undertaken.

 

Key findings

According to Blanco-Kelly et al., (2016), in a cohort of 201 unrelated Spanish families affected by autosomal dominant Retinitis Pigmentosa which was the single largest NR2E3 genotype-phenotype correlation study performed to date in autosomal dominant Retinitis Pigmentosa. Seven of the 201 analyzed families were positive for the p.Gly56Arg, leading to a prevalence of 3.5%. Clinical data were available for 24 subjects. Night blindness was the first noticeable symptom. Visual field loss onset was variable. Loss of visual acuity appeared late in the disease´s evolution. Most of the patients with cataracts (50%) presented it in the third decade of life. Fundus changes showed inter and intra-familiar variability, but most of the patients showed typical RP changes and it was common to find macular affectation (47.4%). Additionally, all patients shared a 104Kb region between D15S1050 and the NR2E3 gene.

This study highlights the importance of p.Gly56Arg in the NR2E3 gene as a common mutation associated with the autosomal dominant form of RP (adRP) and provides new clues to its phenotype, which can allow for better clinical management and genetic counseling of patients and their families.

 

According to Peng et al., (2016), Retinal degeneration is the sole and paramount culprit behind many blindness-related diseases. A few of these include Leber congenital amaurosis (LCA), retinitis pigmentosa (RP), and age-related macular degeneration (AMD).

 

The NR2E3 mutation-associated retinal degeneration epidemiology covered in the report provides historical as well as forecasted NR2E3 mutation-associated retinal degeneration epidemiology [segmented as Total Prevalent cases of Retinal Degeneration, Disease-specific cases of Retinal Degeneration, NR2E3 mutation specific cases of Retinal Degeneration, and Treatable Cases of Retinal degeneration] in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

 

Country-wise NR2E3 mutation-associated retinal degeneration Epidemiology

The epidemiology segment also provides the NR2E3 mutation-associated retinal degeneration epidemiology data and findings across the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

NR2E3 mutation-associated retinal degeneration Drug Chapters

The drug chapter segment of the NR2E3 mutation-associated retinal degeneration report encloses a detailed analysis of NR2E3 mutation-associated retinal degeneration marketed drugs and late-stage (Phase III and Phase II) NR2E3 mutation-associated retinal degeneration pipeline drugs. It also helps understand the NR2E3 mutation-associated retinal degeneration clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging NR2E3 mutation-associated retinal degeneration drugs

The report details the emerging NR2E3 mutation-associated retinal degeneration therapies under the late and mid-stage of development for NR2E3 mutation-associated retinal degeneration treatment.

NR2E3 mutation-associated retinal degeneration Market Outlook

The NR2E3 mutation-associated retinal degeneration market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted NR2E3 mutation-associated retinal degeneration market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

This segment gives a thorough detail of the NR2E3 mutation-associated retinal degeneration market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the NR2E3 mutation-associated retinal degeneration market in the 7MM is expected to witness a major change in the study period 2019–2032.

 

Key findings

This section includes a glimpse of the NR2E3 mutation-associated retinal degeneration market in the 7MM.

 

The United States: NR2E3 mutation-associated retinal degeneration Market Outlook

This section provides the total NR2E3 mutation-associated retinal degeneration market size and market size by therapies in the United States.

 

EU4 and the UK Countries: NR2E3 mutation-associated retinal degeneration Market Outlook

The total NR2E3 mutation-associated retinal degeneration market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan: NR2E3 mutation-associated retinal degeneration Market Outlook

The total NR2E3 mutation-associated retinal degeneration market size and market size by therapies in Japan are also mentioned.

 

NR2E3 mutation-associated retinal degeneration Drug Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the NR2E3 mutation-associated retinal degeneration market or expected to get launched in the market during the study period 2019–2032. The analysis covers the NR2E3 mutation-associated retinal degeneration market uptake by drugs, patient uptake by therapies, and sales of each drug. 

 

This will help in understanding the NR2E3 mutation-associated retinal degeneration drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

 

NR2E3 mutation-associated retinal degeneration Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses NR2E3 mutation-associated retinal degeneration’s key players involved in developing targeted therapeutics.

 

NR2E3 mutation-associated retinal degeneration market clinical trial development activities

The report covers detailed information on collaborations, acquisitions, and mergers, licensing patent details, and other information on NR2E3 mutation-associated retinal degeneration's emerging therapies.

 

NR2E3 mutation-associated retinal degeneration Reimbursement Scenario

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

 

KOL Views

To keep up with current epidemiology and market trends, we take KOLs and SMEs' opinions working in the NR2E3 mutation-associated retinal degeneration domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns along with NR2E3 mutation-associated retinal degeneration market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

 

Competitive Intelligence Analysis

We perform competitive and market intelligence analysis of the NR2E3 mutation-associated retinal degeneration market by using various competitive intelligence tools that include – SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

 

Scope of the Report

• Descriptive overview of NR2E3 mutation-associated retinal degeneration, disease overview, patient journeys, treatment algorithms, diagnosis, and currently available therapies
• Comprehensive insight into the NR2E3 mutation-associated retinal degeneration epidemiology and forecasts in the 7MM
• An all-inclusive account of both the current and emerging therapies for NR2E3 mutation-associated retinal degeneration, along with the assessment of new therapies, is expected to have an impact on the current treatment landscape
• Exhaustive analysis of the NR2E3 mutation-associated retinal degeneration market; historical and forecasted covering drug outreach in the 7MM
• Detailed patient-based market forecasting determines the trends shaping and driving the global NR2E3 mutation-associated retinal degeneration market

 

Report Highlights

• In the coming years, the NR2E3 mutation-associated retinal degeneration market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence NR2E3 mutation-associated retinal degeneration R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition  
• Major players are involved in developing NR2E3 mutation-associated retinal degeneration therapies. The launch of emerging therapies will significantly impact the NR2E3 mutation-associated retinal degeneration market
• A better understanding of NR2E3 mutation-associated retinal degeneration pathogenesis will also contribute to the development of novel therapeutics for NR2E3 mutation-associated retinal degeneration
• Our in-depth analysis of the NR2E3 mutation-associated retinal degeneration pipeline assets across different stages of development (Phase III and Phase II), emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

NR2E3 mutation-associated retinal degeneration Report Insights

• Patient-Based Market Forecasting
• Therapeutic approaches
• NR2E3 mutation-associated retinal degeneration pipeline analysis
• NR2E3 mutation-associated retinal degeneration market size and trends
• NR2E3 mutation-associated retinal degeneration market opportunities
• Impact of upcoming therapies

 

NR2E3 mutation-associated retinal degeneration Report Key Strengths

• 11 years forecast
• 7MM Coverage

 

NR2E3 mutation-associated retinal degeneration epidemiology segmentation

• Key cross competition
• KOL views
• NR2E3 mutation-associated retinal degeneration drugs uptake

 

NR2E3 mutation-associated retinal degeneration Report Assessment

• Current treatment practices
• Unmet needs
• NR2E3 mutation-associated retinal degeneration pipeline product profiles
• NR2E3 mutation-associated retinal degeneration market attractiveness

 

Key Questions

NR2E3 mutation-associated retinal degeneration market insights:

• What would be the NR2E3 mutation-associated retinal degeneration market growth till 2032, and what will be the resultant market size in 2032?
• What was the NR2E3 mutation-associated retinal degeneration drug class share (in percentage) distribution in 2019, and how would it look in 2032?
• What would be the NR2E3 mutation-associated retinal degeneration total market size and market size by therapies across the 7MM during the forecast period (2022–2032)?
• What are the key findings of the market across 7MM, and which country will have the largest NR2E3 mutation-associated retinal degeneration market size during the forecast period (2022–2032)?
• How would the unmet needs affect the NR2E3 mutation-associated retinal degeneration market dynamics and subsequent analysis of the associated trends?

 

NR2E3 mutation-associated retinal degeneration Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of NR2E3 mutation-associated retinal degeneration?
• What is the historical and forecasted NR2E3 mutation-associated retinal degeneration patient pool in the 7MM, and where can one observe the highest patient population and growth opportunities?
• What are the key factors driving the epidemiology trends for seven major markets covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current treatment guidelines and treatment options, in addition to approved therapies for NR2E3 mutation-associated retinal degeneration in the US, Europe, and Japan?
• What are the key collaborations (Industry–Industry, Industry-Academia), mergers and acquisitions, and licensing activities related to NR2E3 mutation-associated retinal degeneration therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for NR2E3 mutation-associated retinal degeneration and its status, along with the challenges faced?

 

Reasons to Buy

• The patient-based market forecast analysis will help in developing business strategies by understanding trends shaping and driving the NR2E3 mutation-associated retinal degeneration market
• Organize sales and marketing efforts by identifying the best opportunities for NR2E3 mutation-associated retinal degeneration in the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan
• Identification of strong upcoming players in the market that will help devise strategies that will help in getting ahead of competitors